Work

Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.10504

Authors: Kelly C. Goldsmith, Kimberly Kayser, Susan G. Groshen, Marc Chioda, Holger C. Thurm, Joseph Chen, Gerson Peltz, Meaghan Granger, John Maris, Katherine K. Matthay, Suzy Ghazarian, Julie R. Park, Esther Berko, Araz Marachelian, Yael P. Mosse

Institutions: Emory University, Children's Healthcare of Atlanta, Vanderbilt University, University of Southern California, Pfizer (United States), Bristol-Myers Squibb (United States), Cook Children's Medical Center, Children's Hospital of Philadelphia, University of California, San Francisco, Children's Hospital Los Angeles, Seattle Children's Hospital, University of Washington

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W3028798998

Cites:

Cited by: 29

Related to: 10